XML 131 R26.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Other Consolidated Financial Statement Detail | 12 Months Ended
--- | ---
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Other Consolidated Financial Statement Detail | Other Consolidated Financial Statement Detail Supplemental Cash Flow Information Supplemental disclosure of cash flow information for the years ended December 31, 2013, 2012 and 2011, is as follows:
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Cash paid during the year for: |  |  |  |  |
Interest | $ | 53.6 |  |  | $ | 65.4 |  |  | $ | 66.7 |
Income taxes | $ | 643.2 |  |  | $ | 526.6 |  |  | $ | 332.7 |
Non-cash Investing and Financing Activity In July and November 2013, the construction of the two office buildings was completed and we started leasing the facilities. Upon completion of the construction of the buildings, we determined that we were no longer considered the owner of the buildings because we do not have any unusual or significant continuing involvement. Consequently, we derecognized the buildings and their associated financing obligation of approximately $161.5 million from our consolidated balance sheet. For additional information related to these transactions, please read Note 11, Property, Plant & Equipment to these consolidated financial statements. In March 2012, upon completion of our acquisition of Stromedix, we recorded $219.2 million of in-process research and development and $48.2 million of goodwill. In addition, we also recorded a contingent consideration obligation of $122.2 million. In September 2011, upon completion of our acquisition of the noncontrolling interest in our joint venture investments in Biogen Dompé SRL and Biogen Dompé Switzerland GmbH, we recorded a contingent consideration obligation of $38.8 million. Other Income (Expense), Net Components of other income (expense), net, are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2013 |  | 2012 |  | 2011
Interest income | $ | 8.2 |  |  | $ | 29.5 |  |  | $ | 19.2 |
Interest expense | (31.9 | ) |  | (36.5 | ) |  | (33.0 | )
Impairments on investments | (2.8 | ) |  | (5.5 | ) |  | (9.9 | )
Gain (loss) on investments, net | 21.7 |  |  | 10.6 |  |  | 18.8 |
Foreign exchange gains (losses), net | (15.2 | ) |  | (2.5 | ) |  | (6.3 | )
Other, net | (14.9 | ) |  | 3.7 |  |  | (2.3 | )
Total other income (expense), net | $ | (34.9 | ) |  | $ | (0.7 | ) |  | $ | (13.5 | )
For 2013 compared to 2012, the change in other income (expense), net was due to a decrease in interest income due to lower average cash, cash equivalent and marketable securities balances primarily related to the use of cash in connection with our acquisition of TYSABRI rights from Elan and the repayment of our 6.0% Senior Notes, a decrease in other, net primarily related to higher non-income based state taxes and higher foreign exchange losses. Accrued Expenses and Other Accrued expenses and other consists of the following:
| As of December 31,
(In millions) | 2013 |  | 2012
Employee compensation and benefits | $ | 343.4 |  |  | $ | 248.5 |
Revenue-related rebates | 264.9 |  |  | 191.0 |
Deferred revenue | 172.7 |  |  | 148.0 |
Royalties and licensing fees | 160.7 |  |  | 45.2 |
Clinical development expenses | 55.2 |  |  | 51.6 |
Current portion of contingent consideration obligations | 29.0 |  |  | 22.4 |
Construction in progress accrual | 25.0 |  |  | 12.3 |
Collaboration expenses | 18.7 |  |  | 37.4 |
Other | 285.6 |  |  | 223.5 |
Total accrued expenses and other | $ | 1,355.2 |  |  | $ | 979.9 |

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration